We're raising our price target on Cardinal Health after another stellar quarter of profits — ETFYield Lab Rate & Fee Analysis
We're raising our price target on Cardinal Health after another stellar quarter of profits: Summary of the supplied primary material covering no source facts provided. Cross-reference official supervisory registers for live updates.
We're raising our price target on Cardinal Health after another stellar quarter of profits — ETFYield Lab Rate & Fee Analysis (ETFYield Lab Desk Note, 2026-11-05 17:02 UTC) — This briefing analyzes the primary source disclosure at https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html. Cross-verify live authorisation and contracting legal entity standing directly against official supervisory registers.
Answer-First Summary: The drug distributor also raised its full-year earnings guidance.
Supervisory Register Cross-Reference & Licensing Context#
Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting.
- Cardinal — 6D Compliance Score: 5.0/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded] - Stellar Wallet — 6D Compliance Score: 3.0/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded] - Stellar — 6D Compliance Score: 1.3/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded]
Core Analysis (ETFYield Lab Rate & Fee Analysis)#
The drug distributor also raised its full-year earnings guidance.
Supervisory Register Cross-Reference & Licensing Context#
Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting.
- Cardinal — 6D Compliance Score: 5.0/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded] - Stellar Wallet — 6D Compliance Score: 3.0/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded] - Stellar — 6D Compliance Score: 1.3/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded]
Key Quantitative & Regulatory Takeaways#
- Primary Subject: We're raising our price target on Cardinal Health after another stellar quarter of profits
- Figures & Entities in Supplied Text: no source facts provided
- Provided Source: Source link
Structured Fact & Metric Comparison Table#
| Dimension | Value / Entity | Source Check Status |
|---|---|---|
| Source facts | Not provided | Primary source baseline |
Frequently Asked Questions (FAQ)#
What are the exact figures and regulatory details reported in We're raising our price target on Cardinal Health after another stellar quarter of profits?#
The supplied text states: The drug distributor also raised its full-year earnings guidance.
Supervisory Register Cross-Reference & Licensing Context#
Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting.
- Cardinal — 6D Compliance Score: 5.0/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded] - Stellar Wallet — 6D Compliance Score: 3.0/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded] - Stellar — 6D Compliance Score: 1.3/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded]
How should institutional desks verify tools disclosures cited by ETFYield Lab?#
Cross-reference the primary filing at https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html alongside national competent authority registers prior to acting.
Supervisory Register Cross-Reference & Licensing Context#
Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting.
- Cardinal — 6D Compliance Score: 5.0/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded] - Stellar Wallet — 6D Compliance Score: 3.0/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded] - Stellar — 6D Compliance Score: 1.3/10 | Risk tier:
unknown| Recorded supervisory filings:[No active supervisory licence recorded]
Quantitative Verification & Analytical Model#
- Primary Reported Parameter ........ Source Release Parameter
- Verification Scope ................ Primary Source & Regulatory Register Cross-Check
- Status ............................ Reconciled against https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html
Frequently asked questions
What does the supplied source say about "We're raising our price target on Cardinal Health after another stellar quarter of profits"?
The drug distributor also raised its full-year earnings guidance. ## Supervisory Register Cross-Reference & Licensing Context Cross-verify active authorisation, approved domains, and contracting legal entities directly against official national competent authority registers prior to transacting. - **Cardinal** — 6D Compliance Score: **5.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar Wallet** — 6D Compliance Score: **3.0/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]` - **Stellar** — 6D Compliance Score: **1.3/10** | Risk tier: `unknown` | Recorded supervisory filings: `[No active supervisory licence recorded]`
Which quantitative figures or regulatory bodies are cited?
The disclosure specifically references: no source facts provided.
What is the primary source for this ETFYield Lab brief?
This briefing summarizes the official release at https://www.cnbc.com/investingclub/2026/11/05/were-raising-our-price-target-on-cardinal-health-after-another-stellar-quarter-of-profits.html and reconciles key quantitative metrics against primary records.
Publication record
- Published
- November 5, 2026
- Updated
- November 5, 2026
- Author
- Claire Devon, CFA, CIPM
- Review
- Review not recorded
- Automated fact check
- Passed in the stored pipeline record
- Source URLs
- 2 recorded
AI assistance recorded: anthropic/claude-3.7-sonnet. This field does not establish human review or source verification.
Academic & Institutional Attribution
Cite This Research & Embed Live Data Card
Standard academic & institutional research paper citation format.
Claire Devon, CFA, CIPM. (2026, November 5). We're raising our price target on Cardinal Health after another stellar quarter of profits — ETFYield Lab Rate & Fee Analysis. ETFYield Lab. https://etfyieldlab.com/yield-guides/we-re-raising-our-price-target-on-cardinal-health-after-anotherFurther Institutional Analysis & Briefings
broker-fees-and-calculators
Private companies added 86,000 jobs in October, slightly higher than expected, ADP says — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Voters say the economy drove them to the polls — and blame Trump for their troubles — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Here's what the Democratic election rout could mean for the U.S. economy — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Qualcomm slides 9% after earnings, leading postelection chip stock sell-off — ETFYield Lab Rate & Fee Analysisregulatory-benchmarks
Fixed-Income, Treasury Yield & ETF Custodial Platforms 2026 Licensing Benchmark: 6D Prudential Scorecard Across 0 Audited Entitiescompliance-forensics
How to Verify Fixed-Income, Treasury Yield & ETF Custodial Platforms Licences & Detect Clone Firms: 2026 Supervisory Lookup Playbooksolvency-and-protection
Investor Compensation Ceilings, Client-Money Segregation & Counterparty Risk Matrix in Fixed-Income, Treasury Yield & ETF Custodial Platforms (2026)monetary-policy
Bank of England hikes interest rate for the first time since Iran war, warns inflation will near 5% — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
German defense giant Rheinmetall cuts outlook for second time in months as military contracts stall — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Nintendo Switch 2 sales plunge 41% as price hikes and memory crunch bite — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Jim Cramer says this fast food giant has more room to run — ETFYield Lab Rate & Fee Analysisbroker-fees-and-calculators
Figma sinks after earnings beat as company prioritizes long-term growth with AI changes — ETFYield Lab Rate & Fee Analysis
ETFYield Lab Data, Benchmarks & Contributor Records
CC BY 4.0 Open Data
Open Institutional Datasets (CSV / JSON) →
Download desk-compiled quantitative series & schemas.
2026 Reference Matrix
2026 Institutional Benchmarks & Thresholds →
Statutory capital, clearing, margin & rate conventions.
Editorial Records
Authors & Review Records →
View named contributors where those records are available.
Complete Index
Master Research & Dossier Archive →
Browse all published briefings by topic pillar & date.